| scholarly article | Q13442814 |
| P50 | author | Corrado Ficorella | Q110910561 |
| Katia Cannita | Q110910563 | ||
| P2093 | author name string | Alessandra Tessitore | |
| Gino Coletti | |||
| Edoardo Alesse | |||
| Enrico Ricevuto | |||
| Alberto Bafile | |||
| Azzurra Irelli | |||
| Laura Pizzorno | |||
| Paola Lanfiuti Baldi | |||
| Stefania Paradisi | |||
| Tina Sidoni | |||
| Valentina Cocciolone | |||
| Valter Resta | |||
| Lucia Rinaldi | |||
| Giuseppe Calvisi | |||
| Valentina Mastroiaco | |||
| Antonella Dal Mas | |||
| Antonietta Ciccozzi | |||
| P2860 | cites work | Comprehensive molecular portraits of human breast tumours | Q24630844 |
| Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial | Q27851705 | ||
| Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study | Q27851763 | ||
| Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial | Q28254919 | ||
| Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA) | Q28291395 | ||
| Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies | Q29617680 | ||
| A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer | Q33374609 | ||
| Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†. | Q33683126 | ||
| Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials | Q33753705 | ||
| Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: a systematic review and meta-analysis | Q33969694 | ||
| PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors | Q34296476 | ||
| Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences | Q34654793 | ||
| An integrative analysis of PIK3CA mutation, PTEN, and INPP4B expression in terms of trastuzumab efficacy in HER2-positive breast cancer | Q34776985 | ||
| Dose-dense nonpegylated liposomal Doxorubicin and docetaxel combination in breast cancer: dose-finding study | Q35057287 | ||
| Can ki-67 play a role in prediction of breast cancer patients' response to neoadjuvant chemotherapy? | Q35160045 | ||
| Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer | Q36064908 | ||
| Prognostic role of PIK3CA mutations of cell-free DNA in early-stage triple negative breast cancer | Q36467458 | ||
| PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer | Q36678668 | ||
| Axillary lymph node status, adjusted for pathologic complete response in breast and axilla after neoadjuvant chemotherapy, predicts differential disease-free survival in breast cancer | Q36897778 | ||
| Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer | Q36976208 | ||
| Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial | Q37049920 | ||
| An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer | Q37187915 | ||
| PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer | Q37380424 | ||
| A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints | Q38015026 | ||
| Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis | Q38188183 | ||
| PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. | Q39767744 | ||
| Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group | Q40510447 | ||
| Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. | Q40675977 | ||
| Evolving concepts in the systemic drug therapy of breast cancer | Q41579743 | ||
| The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes | Q42511189 | ||
| A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients | Q43060768 | ||
| A nomogram based on the expression of Ki-67, steroid hormone receptors status and number of chemotherapy courses to predict pathological complete remission after preoperative chemotherapy for breast cancer. | Q43062601 | ||
| Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall | Q43180234 | ||
| The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. | Q44618276 | ||
| Design and analysis of phase I clinical trials | Q44888410 | ||
| Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer | Q45287928 | ||
| Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. | Q45945230 | ||
| Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer | Q46043819 | ||
| Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy | Q46532153 | ||
| Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial | Q46764831 | ||
| Dose density in breast cancer: a simple message? | Q46839622 | ||
| Phase II study of dose-dense sequential doxorubicin and docetaxel for patients with advanced operable and inoperable breast cancer. | Q46848282 | ||
| Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. | Q50666942 | ||
| Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer. | Q52857952 | ||
| PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. | Q52874022 | ||
| Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. | Q52893849 | ||
| Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44). | Q53752984 | ||
| Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a r | Q57129922 | ||
| Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu | Q57578575 | ||
| Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort | Q57579888 | ||
| Breast tumour response to primary chemotherapy predicts local and distant control as well as survival | Q70901518 | ||
| Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group | Q73042198 | ||
| Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy | Q74611825 | ||
| Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis | Q81353372 | ||
| Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer | Q81709409 | ||
| A dose-dense schedule of docetaxel followed by doxorubicin and cyclophosphamide as neoadjuvant treatment for breast cancer: results from a phase II study | Q84818422 | ||
| P433 | issue | 44 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 27380-27396 | |
| P577 | publication date | 2018-06-08 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations. | |
| P478 | volume | 9 |
Search more.